SEC22B and neoplasm: Consistent with this finding, the induction of a CTL immune response in the tumor draining lymph nodes is abolished in Zbtb46-DTR–transgenic mice that do not develop cDC [40] and in Sec22b-/- mice that possess cDC1 deficient in cross-presentation [51].